Filing Flows › Alkermes (ALKS) › Guidance & outlook
Alkermes (ALKS) guidance and outlook
Alkermes' 10-Q filed Nov 3, 2026 makes 5 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 3, 2026
- The key marketed products discussed below have generated, or are expected to generate, significant revenues for us.
- As part of our ongoing R&D efforts, we have devoted, and will continue to devote, significant resources to conducting preclinical work and clinical studies to advance the development of new pharmaceutical products.
- Based on our most recent analysis, amortization of intangible assets included within our consolidated balance sheet at September 30, 2026 is expected to be approximately $74.7 million, $83.7 million, $112.7 million, $122.3 million and $128.6 million in the years ending December 31, 2026 through 2030, respectively.
- We expect achievement of the CVR Milestone to be determined by the end of 2027 and used a discount rate of 7.08%;
- If these projects are not successfully developed, the sales and profitability of the Company may be adversely affected in future periods.
Alkermes' latest quarter
Alkermes, Q3 2026: revenue $480M (+22% year over year), operating margin 7.5%, net earnings $16.3M, operating cash flow $93.5M. The chart follows the revenue to costs, profit and cash.
Questions
What does Alkermes expect?
The key marketed products discussed below have generated, or are expected to generate, significant revenues for us. As part of our ongoing R&D efforts, we have devoted, and will continue to devote, significant resources to conducting preclinical work and clinical studies to advance the development of new pharmaceutical products. Based on our most recent analysis, amortization of intangible assets included within our consolidated balance sheet at September 30, 2026 is expected to be approximately $74.7 million, $83.7 million, $112.7 million, $122.3 million and $128.6 million in the years ending
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.